---
title: CROs offering Medicinal Chemistry with Oligonucleotide
path: /explore/medicinal-chemistry/oligonucleotide
companies_count: 12
---

# CROs offering Medicinal Chemistry with Oligonucleotide

12 published CROs match Medicinal Chemistry and Oligonucleotide.

Locations in this set include United States, China, India, United Kingdom, Japan, and South Korea.

Capabilities that show up most often in this set: Discovery Research, Computational & In-Silico Drug Discovery, High-Throughput Screening, Preclinical In Vitro Studies, and Bioanalysis.

## Matching companies

- [Aragen Life Sciences](/companies/aragen)
  - Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.
- [Axcelead Drug Discovery Partners, Inc.](/companies/axcelead)
  - Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.
- [Certara](/companies/certara)
  - Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.
- [ChemDiv](/companies/chemdiv)
  - ChemDiv is a fully integrated target-to-clinic CRO headquartered in San Diego, CA, offering drug discovery services including medicinal chemistry, CADD, ADME/DMPK, toxicology, and custom synthesis alongside the industry's largest commercial screening library of 1.6M compounds.
- [ChemPartner](/companies/chempartner)
  - Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.
- [HitGen Inc.](/companies/hitgen)
  - HitGen Inc. provides drug discovery services built on DNA-encoded library (DEL), fragment-based (FBDD/SBDD) and computational platforms for pharmaceutical and biotech clients. The company also offers oligonucleotide CDMO services and reports serving more than 600 clients globally.
- [Pharmaron](/companies/pharmaron)
  - Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
- [Sapala Organics](/companies/sapalaorganics)
  - Custom synthesis of nucleic acid building blocks, modified phosphoramidites and oligonucleotide delivery compounds, plus FTE-based CRO and fee-for-service CDMO engagements. Orthogonal analytical services serve clients from early R&D through pharma innovators.
- [Syngene International](/companies/syngeneintl)
  - Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
- [Taros Chemicals GmbH & Co. KG](/companies/tarosdiscovery)
  - Independent chemistry CRO in Dortmund, Germany offering discovery chemistry, custom synthesis, medicinal chemistry, and process development for pharma, biotech, and chemical companies since 1999.
- [Tigermed](/companies/tigermedgrp)
  - Leading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
- [WuXi AppTec](/companies/wuxiapptec)
  - Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.